Insider Selling: Claritev (NYSE:CTEV) SVP Sells $288,677.44 in Stock

Claritev (NYSE:CTEV) SVP William Mintz sold 8,431 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $34.24, for a total value of $288,677.44. Following the completion of the transaction, the senior vice president owned 71,195 shares in the company, valued at approximately $2,437,716.80. This trade represents a 10.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Claritev Stock Performance

Shares of NYSE:CTEV opened at $38.51 on Friday. Claritev has a 1 year low of $11.50 and a 1 year high of $74.07. The stock has a market capitalization of $652.74 million, a P/E ratio of -2.26 and a beta of 0.74. The stock has a 50-day simple moving average of $29.85 and a 200-day simple moving average of $24.05.

Analyst Upgrades and Downgrades

Several research firms have issued reports on CTEV. Zacks Research downgraded shares of Claritev from a “hold” rating to a “strong sell” rating in a research note on Friday, July 17th. Barclays initiated coverage on shares of Claritev in a research note on Friday, April 24th. They issued an “overweight” rating and a $28.00 target price on the stock. Canaccord Genuity Group lifted their target price on shares of Claritev from $37.00 to $43.00 and gave the company a “buy” rating in a report on Monday, August 10th. Wall Street Zen raised shares of Claritev from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $73.00 price target on shares of Claritev in a report on Wednesday. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Claritev currently has an average rating of “Hold” and an average price target of $42.83.

Hedge Funds Weigh In On Claritev

Institutional investors and hedge funds have recently bought and sold shares of the stock. FAS Wealth Partners Inc. grew its position in Claritev by 49.5% in the first quarter. FAS Wealth Partners Inc. now owns 46,477 shares of the company’s stock valued at $759,000 after acquiring an additional 15,380 shares in the last quarter. Bank of America Corp DE lifted its position in shares of Claritev by 146.6% during the first quarter. Bank of America Corp DE now owns 97,795 shares of the company’s stock worth $1,598,000 after purchasing an additional 58,133 shares in the last quarter. RBF Capital LLC lifted its position in shares of Claritev by 0.8% during the first quarter. RBF Capital LLC now owns 135,314 shares of the company’s stock worth $2,211,000 after purchasing an additional 1,127 shares in the last quarter. Public Employees Retirement System of Ohio purchased a new position in shares of Claritev in the first quarter valued at $38,000. Finally, State of Wyoming boosted its stake in shares of Claritev by 239.2% in the first quarter. State of Wyoming now owns 2,018 shares of the company’s stock valued at $33,000 after purchasing an additional 1,423 shares during the period. Hedge funds and other institutional investors own 87.15% of the company’s stock.

Claritev Company Profile

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.